Global Human Plasma-derived Hyperimmune Product Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
Page: 107
Published Date: 07 Aug 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Human Plasma-derived Hyperimmune Product market size was valued at USD 1921 million in 2022 and is forecast to a readjusted size of USD 2866.8 million by 2029 with a CAGR of 5.9% during review period.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
The Global Info Research report includes an overview of the development of the Human Plasma-derived Hyperimmune Product industry chain, the market status of Government Institution (Hepatitis B Immunoglobulins, Rabies Immunoglobulins), Private Sector (Hepatitis B Immunoglobulins, Rabies Immunoglobulins), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Human Plasma-derived Hyperimmune Product.
Regionally, the report analyzes the Human Plasma-derived Hyperimmune Product markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Human Plasma-derived Hyperimmune Product market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Human Plasma-derived Hyperimmune Product market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Human Plasma-derived Hyperimmune Product industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Hepatitis B Immunoglobulins, Rabies Immunoglobulins).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Human Plasma-derived Hyperimmune Product market.
Regional Analysis: The report involves examining the Human Plasma-derived Hyperimmune Product market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Human Plasma-derived Hyperimmune Product market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Human Plasma-derived Hyperimmune Product:
Company Analysis: Report covers individual Human Plasma-derived Hyperimmune Product manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Human Plasma-derived Hyperimmune Product This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Government Institution, Private Sector).
Technology Analysis: Report covers specific technologies relevant to Human Plasma-derived Hyperimmune Product. It assesses the current state, advancements, and potential future developments in Human Plasma-derived Hyperimmune Product areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Human Plasma-derived Hyperimmune Product market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Human Plasma-derived Hyperimmune Product market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Market segment by Application
Government Institution
Private Sector
Others
Major players covered
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Plasma-derived Hyperimmune Product product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Plasma-derived Hyperimmune Product, with price, sales, revenue and global market share of Human Plasma-derived Hyperimmune Product from 2018 to 2023.
Chapter 3, the Human Plasma-derived Hyperimmune Product competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Plasma-derived Hyperimmune Product breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Human Plasma-derived Hyperimmune Product market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Plasma-derived Hyperimmune Product.
Chapter 14 and 15, to describe Human Plasma-derived Hyperimmune Product sales channel, distributors, customers, research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Human Plasma-derived Hyperimmune Product
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Human Plasma-derived Hyperimmune Product Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Hepatitis B Immunoglobulins
1.3.3 Rabies Immunoglobulins
1.3.4 Tetanus Immunoglobulins
1.3.5 Rho(D) Immunoglobulins
1.3.6 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Human Plasma-derived Hyperimmune Product Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Government Institution
1.4.3 Private Sector
1.4.4 Others
1.5 Global Human Plasma-derived Hyperimmune Product Market Size & Forecast
1.5.1 Global Human Plasma-derived Hyperimmune Product Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Human Plasma-derived Hyperimmune Product Sales Quantity (2018-2029)
1.5.3 Global Human Plasma-derived Hyperimmune Product Average Price (2018-2029)
2.1 CSL Behring
2.1.1 CSL Behring Details
2.1.2 CSL Behring Major Business
2.1.3 CSL Behring Human Plasma-derived Hyperimmune Product Product and Services
2.1.4 CSL Behring Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 CSL Behring Recent Developments/Updates
2.2 Grifols
2.2.1 Grifols Details
2.2.2 Grifols Major Business
2.2.3 Grifols Human Plasma-derived Hyperimmune Product Product and Services
2.2.4 Grifols Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Grifols Recent Developments/Updates
2.3 Biotest
2.3.1 Biotest Details
2.3.2 Biotest Major Business
2.3.3 Biotest Human Plasma-derived Hyperimmune Product Product and Services
2.3.4 Biotest Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Biotest Recent Developments/Updates
2.4 Kedrion
2.4.1 Kedrion Details
2.4.2 Kedrion Major Business
2.4.3 Kedrion Human Plasma-derived Hyperimmune Product Product and Services
2.4.4 Kedrion Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Kedrion Recent Developments/Updates
2.5 CBPO
2.5.1 CBPO Details
2.5.2 CBPO Major Business
2.5.3 CBPO Human Plasma-derived Hyperimmune Product Product and Services
2.5.4 CBPO Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 CBPO Recent Developments/Updates
2.6 Emergent (Cangene)
2.6.1 Emergent (Cangene) Details
2.6.2 Emergent (Cangene) Major Business
2.6.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product and Services
2.6.4 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Emergent (Cangene) Recent Developments/Updates
2.7 Kamada
2.7.1 Kamada Details
2.7.2 Kamada Major Business
2.7.3 Kamada Human Plasma-derived Hyperimmune Product Product and Services
2.7.4 Kamada Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Kamada Recent Developments/Updates
2.8 CNBG
2.8.1 CNBG Details
2.8.2 CNBG Major Business
2.8.3 CNBG Human Plasma-derived Hyperimmune Product Product and Services
2.8.4 CNBG Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 CNBG Recent Developments/Updates
2.9 Hualan Bio
2.9.1 Hualan Bio Details
2.9.2 Hualan Bio Major Business
2.9.3 Hualan Bio Human Plasma-derived Hyperimmune Product Product and Services
2.9.4 Hualan Bio Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Hualan Bio Recent Developments/Updates
2.10 Shanghai RAAS
2.10.1 Shanghai RAAS Details
2.10.2 Shanghai RAAS Major Business
2.10.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product and Services
2.10.4 Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Shanghai RAAS Recent Developments/Updates
2.11 Sichuan Yuanda Shuyang
2.11.1 Sichuan Yuanda Shuyang Details
2.11.2 Sichuan Yuanda Shuyang Major Business
2.11.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product and Services
2.11.4 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
2.12 ADMA Biologics
2.12.1 ADMA Biologics Details
2.12.2 ADMA Biologics Major Business
2.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Product and Services
2.12.4 ADMA Biologics Human Plasma-derived Hyperimmune Product Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 ADMA Biologics Recent Developments/Updates
3.1 Global Human Plasma-derived Hyperimmune Product Sales Quantity by Manufacturer (2018-2023)
3.2 Global Human Plasma-derived Hyperimmune Product Revenue by Manufacturer (2018-2023)
3.3 Global Human Plasma-derived Hyperimmune Product Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Human Plasma-derived Hyperimmune Product by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Human Plasma-derived Hyperimmune Product Manufacturer Market Share in 2022
3.4.2 Top 6 Human Plasma-derived Hyperimmune Product Manufacturer Market Share in 2022
3.5 Human Plasma-derived Hyperimmune Product Market: Overall Company Footprint Analysis
3.5.1 Human Plasma-derived Hyperimmune Product Market: Region Footprint
3.5.2 Human Plasma-derived Hyperimmune Product Market: Company Product Type Footprint
3.5.3 Human Plasma-derived Hyperimmune Product Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Human Plasma-derived Hyperimmune Product Market Size by Region
4.1.1 Global Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2018-2029)
4.1.2 Global Human Plasma-derived Hyperimmune Product Consumption Value by Region (2018-2029)
4.1.3 Global Human Plasma-derived Hyperimmune Product Average Price by Region (2018-2029)
4.2 North America Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029)
4.3 Europe Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029)
4.4 Asia-Pacific Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029)
4.5 South America Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029)
4.6 Middle East and Africa Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029)
5.1 Global Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2029)
5.2 Global Human Plasma-derived Hyperimmune Product Consumption Value by Type (2018-2029)
5.3 Global Human Plasma-derived Hyperimmune Product Average Price by Type (2018-2029)
6.1 Global Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2029)
6.2 Global Human Plasma-derived Hyperimmune Product Consumption Value by Application (2018-2029)
6.3 Global Human Plasma-derived Hyperimmune Product Average Price by Application (2018-2029)
7.1 North America Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2029)
7.2 North America Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2029)
7.3 North America Human Plasma-derived Hyperimmune Product Market Size by Country
7.3.1 North America Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2018-2029)
7.3.2 North America Human Plasma-derived Hyperimmune Product Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8.1 Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2029)
8.2 Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2029)
8.3 Europe Human Plasma-derived Hyperimmune Product Market Size by Country
8.3.1 Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2018-2029)
8.3.2 Europe Human Plasma-derived Hyperimmune Product Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9.1 Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Human Plasma-derived Hyperimmune Product Market Size by Region
9.3.1 Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Human Plasma-derived Hyperimmune Product Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10.1 South America Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2029)
10.2 South America Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2029)
10.3 South America Human Plasma-derived Hyperimmune Product Market Size by Country
10.3.1 South America Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2018-2029)
10.3.2 South America Human Plasma-derived Hyperimmune Product Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11.1 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Human Plasma-derived Hyperimmune Product Market Size by Country
11.3.1 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Human Plasma-derived Hyperimmune Product Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12.1 Human Plasma-derived Hyperimmune Product Market Drivers
12.2 Human Plasma-derived Hyperimmune Product Market Restraints
12.3 Human Plasma-derived Hyperimmune Product Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13.1 Raw Material of Human Plasma-derived Hyperimmune Product and Key Manufacturers
13.2 Manufacturing Costs Percentage of Human Plasma-derived Hyperimmune Product
13.3 Human Plasma-derived Hyperimmune Product Production Process
13.4 Human Plasma-derived Hyperimmune Product Industrial Chain
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Human Plasma-derived Hyperimmune Product Typical Distributors
14.3 Human Plasma-derived Hyperimmune Product Typical Customers
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Human Plasma-derived Hyperimmune Product Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Human Plasma-derived Hyperimmune Product Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 4. CSL Behring Major Business
Table 5. CSL Behring Human Plasma-derived Hyperimmune Product Product and Services
Table 6. CSL Behring Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. CSL Behring Recent Developments/Updates
Table 8. Grifols Basic Information, Manufacturing Base and Competitors
Table 9. Grifols Major Business
Table 10. Grifols Human Plasma-derived Hyperimmune Product Product and Services
Table 11. Grifols Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Grifols Recent Developments/Updates
Table 13. Biotest Basic Information, Manufacturing Base and Competitors
Table 14. Biotest Major Business
Table 15. Biotest Human Plasma-derived Hyperimmune Product Product and Services
Table 16. Biotest Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Biotest Recent Developments/Updates
Table 18. Kedrion Basic Information, Manufacturing Base and Competitors
Table 19. Kedrion Major Business
Table 20. Kedrion Human Plasma-derived Hyperimmune Product Product and Services
Table 21. Kedrion Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Kedrion Recent Developments/Updates
Table 23. CBPO Basic Information, Manufacturing Base and Competitors
Table 24. CBPO Major Business
Table 25. CBPO Human Plasma-derived Hyperimmune Product Product and Services
Table 26. CBPO Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. CBPO Recent Developments/Updates
Table 28. Emergent (Cangene) Basic Information, Manufacturing Base and Competitors
Table 29. Emergent (Cangene) Major Business
Table 30. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product and Services
Table 31. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Emergent (Cangene) Recent Developments/Updates
Table 33. Kamada Basic Information, Manufacturing Base and Competitors
Table 34. Kamada Major Business
Table 35. Kamada Human Plasma-derived Hyperimmune Product Product and Services
Table 36. Kamada Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Kamada Recent Developments/Updates
Table 38. CNBG Basic Information, Manufacturing Base and Competitors
Table 39. CNBG Major Business
Table 40. CNBG Human Plasma-derived Hyperimmune Product Product and Services
Table 41. CNBG Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. CNBG Recent Developments/Updates
Table 43. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 44. Hualan Bio Major Business
Table 45. Hualan Bio Human Plasma-derived Hyperimmune Product Product and Services
Table 46. Hualan Bio Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Hualan Bio Recent Developments/Updates
Table 48. Shanghai RAAS Basic Information, Manufacturing Base and Competitors
Table 49. Shanghai RAAS Major Business
Table 50. Shanghai RAAS Human Plasma-derived Hyperimmune Product Product and Services
Table 51. Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Shanghai RAAS Recent Developments/Updates
Table 53. Sichuan Yuanda Shuyang Basic Information, Manufacturing Base and Competitors
Table 54. Sichuan Yuanda Shuyang Major Business
Table 55. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product and Services
Table 56. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Sichuan Yuanda Shuyang Recent Developments/Updates
Table 58. ADMA Biologics Basic Information, Manufacturing Base and Competitors
Table 59. ADMA Biologics Major Business
Table 60. ADMA Biologics Human Plasma-derived Hyperimmune Product Product and Services
Table 61. ADMA Biologics Human Plasma-derived Hyperimmune Product Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. ADMA Biologics Recent Developments/Updates
Table 63. Global Human Plasma-derived Hyperimmune Product Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 64. Global Human Plasma-derived Hyperimmune Product Revenue by Manufacturer (2018-2023) & (USD Million)
Table 65. Global Human Plasma-derived Hyperimmune Product Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 66. Market Position of Manufacturers in Human Plasma-derived Hyperimmune Product, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 67. Head Office and Human Plasma-derived Hyperimmune Product Production Site of Key Manufacturer
Table 68. Human Plasma-derived Hyperimmune Product Market: Company Product Type Footprint
Table 69. Human Plasma-derived Hyperimmune Product Market: Company Product Application Footprint
Table 70. Human Plasma-derived Hyperimmune Product New Market Entrants and Barriers to Market Entry
Table 71. Human Plasma-derived Hyperimmune Product Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2018-2023) & (K Units)
Table 73. Global Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2024-2029) & (K Units)
Table 74. Global Human Plasma-derived Hyperimmune Product Consumption Value by Region (2018-2023) & (USD Million)
Table 75. Global Human Plasma-derived Hyperimmune Product Consumption Value by Region (2024-2029) & (USD Million)
Table 76. Global Human Plasma-derived Hyperimmune Product Average Price by Region (2018-2023) & (US$/Unit)
Table 77. Global Human Plasma-derived Hyperimmune Product Average Price by Region (2024-2029) & (US$/Unit)
Table 78. Global Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Global Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Global Human Plasma-derived Hyperimmune Product Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Global Human Plasma-derived Hyperimmune Product Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Global Human Plasma-derived Hyperimmune Product Average Price by Type (2018-2023) & (US$/Unit)
Table 83. Global Human Plasma-derived Hyperimmune Product Average Price by Type (2024-2029) & (US$/Unit)
Table 84. Global Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Global Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Global Human Plasma-derived Hyperimmune Product Consumption Value by Application (2018-2023) & (USD Million)
Table 87. Global Human Plasma-derived Hyperimmune Product Consumption Value by Application (2024-2029) & (USD Million)
Table 88. Global Human Plasma-derived Hyperimmune Product Average Price by Application (2018-2023) & (US$/Unit)
Table 89. Global Human Plasma-derived Hyperimmune Product Average Price by Application (2024-2029) & (US$/Unit)
Table 90. North America Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2023) & (K Units)
Table 91. North America Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2024-2029) & (K Units)
Table 92. North America Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2023) & (K Units)
Table 93. North America Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2024-2029) & (K Units)
Table 94. North America Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2018-2023) & (K Units)
Table 95. North America Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2024-2029) & (K Units)
Table 96. North America Human Plasma-derived Hyperimmune Product Consumption Value by Country (2018-2023) & (USD Million)
Table 97. North America Human Plasma-derived Hyperimmune Product Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2023) & (K Units)
Table 99. Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2024-2029) & (K Units)
Table 100. Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2023) & (K Units)
Table 101. Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2024-2029) & (K Units)
Table 102. Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2018-2023) & (K Units)
Table 103. Europe Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2024-2029) & (K Units)
Table 104. Europe Human Plasma-derived Hyperimmune Product Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Human Plasma-derived Hyperimmune Product Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2024-2029) & (K Units)
Table 108. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2024-2029) & (K Units)
Table 110. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2018-2023) & (K Units)
Table 111. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2024-2029) & (K Units)
Table 112. Asia-Pacific Human Plasma-derived Hyperimmune Product Consumption Value by Region (2018-2023) & (USD Million)
Table 113. Asia-Pacific Human Plasma-derived Hyperimmune Product Consumption Value by Region (2024-2029) & (USD Million)
Table 114. South America Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2023) & (K Units)
Table 115. South America Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2024-2029) & (K Units)
Table 116. South America Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2023) & (K Units)
Table 117. South America Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2024-2029) & (K Units)
Table 118. South America Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2018-2023) & (K Units)
Table 119. South America Human Plasma-derived Hyperimmune Product Sales Quantity by Country (2024-2029) & (K Units)
Table 120. South America Human Plasma-derived Hyperimmune Product Consumption Value by Country (2018-2023) & (USD Million)
Table 121. South America Human Plasma-derived Hyperimmune Product Consumption Value by Country (2024-2029) & (USD Million)
Table 122. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2018-2023) & (K Units)
Table 123. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Type (2024-2029) & (K Units)
Table 124. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2018-2023) & (K Units)
Table 127. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity by Region (2024-2029) & (K Units)
Table 128. Middle East & Africa Human Plasma-derived Hyperimmune Product Consumption Value by Region (2018-2023) & (USD Million)
Table 129. Middle East & Africa Human Plasma-derived Hyperimmune Product Consumption Value by Region (2024-2029) & (USD Million)
Table 130. Human Plasma-derived Hyperimmune Product Raw Material
Table 131. Key Manufacturers of Human Plasma-derived Hyperimmune Product Raw Materials
Table 132. Human Plasma-derived Hyperimmune Product Typical Distributors
Table 133. Human Plasma-derived Hyperimmune Product Typical Customers
List of Figures
Figure 1. Human Plasma-derived Hyperimmune Product Picture
Figure 2. Global Human Plasma-derived Hyperimmune Product Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Type in 2022
Figure 4. Hepatitis B Immunoglobulins Examples
Figure 5. Rabies Immunoglobulins Examples
Figure 6. Tetanus Immunoglobulins Examples
Figure 7. Rho(D) Immunoglobulins Examples
Figure 8. Other Examples
Figure 9. Global Human Plasma-derived Hyperimmune Product Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 10. Global Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Application in 2022
Figure 11. Government Institution Examples
Figure 12. Private Sector Examples
Figure 13. Others Examples
Figure 14. Global Human Plasma-derived Hyperimmune Product Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Human Plasma-derived Hyperimmune Product Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Human Plasma-derived Hyperimmune Product Sales Quantity (2018-2029) & (K Units)
Figure 17. Global Human Plasma-derived Hyperimmune Product Average Price (2018-2029) & (US$/Unit)
Figure 18. Global Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Manufacturer in 2022
Figure 19. Global Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Manufacturer in 2022
Figure 20. Producer Shipments of Human Plasma-derived Hyperimmune Product by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 21. Top 3 Human Plasma-derived Hyperimmune Product Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Top 6 Human Plasma-derived Hyperimmune Product Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Global Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Region (2018-2029)
Figure 24. Global Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Region (2018-2029)
Figure 25. North America Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029) & (USD Million)
Figure 26. Europe Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029) & (USD Million)
Figure 27. Asia-Pacific Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029) & (USD Million)
Figure 28. South America Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029) & (USD Million)
Figure 29. Middle East & Africa Human Plasma-derived Hyperimmune Product Consumption Value (2018-2029) & (USD Million)
Figure 30. Global Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Type (2018-2029)
Figure 31. Global Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Type (2018-2029)
Figure 32. Global Human Plasma-derived Hyperimmune Product Average Price by Type (2018-2029) & (US$/Unit)
Figure 33. Global Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Application (2018-2029)
Figure 34. Global Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Application (2018-2029)
Figure 35. Global Human Plasma-derived Hyperimmune Product Average Price by Application (2018-2029) & (US$/Unit)
Figure 36. North America Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Type (2018-2029)
Figure 37. North America Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Application (2018-2029)
Figure 38. North America Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Country (2018-2029)
Figure 39. North America Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Country (2018-2029)
Figure 40. United States Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Canada Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Mexico Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Europe Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Type (2018-2029)
Figure 44. Europe Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Application (2018-2029)
Figure 45. Europe Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Country (2018-2029)
Figure 46. Europe Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Country (2018-2029)
Figure 47. Germany Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. France Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. United Kingdom Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Russia Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Italy Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Type (2018-2029)
Figure 53. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Application (2018-2029)
Figure 54. Asia-Pacific Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Region (2018-2029)
Figure 55. Asia-Pacific Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Region (2018-2029)
Figure 56. China Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Japan Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Korea Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. India Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Southeast Asia Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Australia Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. South America Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Type (2018-2029)
Figure 63. South America Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Application (2018-2029)
Figure 64. South America Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Country (2018-2029)
Figure 65. South America Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Country (2018-2029)
Figure 66. Brazil Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Argentina Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Type (2018-2029)
Figure 69. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Application (2018-2029)
Figure 70. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Quantity Market Share by Region (2018-2029)
Figure 71. Middle East & Africa Human Plasma-derived Hyperimmune Product Consumption Value Market Share by Region (2018-2029)
Figure 72. Turkey Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Egypt Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Saudi Arabia Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. South Africa Human Plasma-derived Hyperimmune Product Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Human Plasma-derived Hyperimmune Product Market Drivers
Figure 77. Human Plasma-derived Hyperimmune Product Market Restraints
Figure 78. Human Plasma-derived Hyperimmune Product Market Trends
Figure 79. Porters Five Forces Analysis
Figure 80. Manufacturing Cost Structure Analysis of Human Plasma-derived Hyperimmune Product in 2022
Figure 81. Manufacturing Process Analysis of Human Plasma-derived Hyperimmune Product
Figure 82. Human Plasma-derived Hyperimmune Product Industrial Chain
Figure 83. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
CSL Behring Grifols Biotest Kedrion CBPO Emergent (Cangene) Kamada CNBG Hualan Bio Shanghai RAAS Sichuan Yuanda Shuyang ADMA Biologics
Related Reports
07 Aug 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
